Collegium Pharmaceutical reported record third-quarter revenue of $216.3 million, up 3% from a year earlier, as growth in its ADHD medicines offset the contribution from its established pain portfolio. The company also reported $121.6 million in adjusted EBITDA and reaffirmed its 2026 financial guidance.
The quarter included the first full three months of AZSTARYS sales under Collegium’s ownership. Collegium also said it expects to complete a previously announced $50 million accelerated share repurchase before year-end.
Key details
- JORNAY PM continued to grow: Revenue rose 24% year over year to a quarterly record of $51.9 million. Prescriptions increased 16%, and nearly 33,000 healthcare providers prescribed the ADHD medicine—up 19% from a year earlier.
- AZSTARYS added $26.5 million in revenue: This was its first full quarter under Collegium’s ownership. Prescriptions grew nearly 2% year over year, an improvement from the product’s annual prescription decline in 2025 before the acquisition.
- The ADHD business is becoming a larger part of Collegium: The company said its ADHD franchise accounted for more than 36% of total revenue in the quarter.
- The pain portfolio generated $138.0 million in revenue, providing a substantial portion of quarterly sales.
- 2026 guidance was reaffirmed. The results announcement did not include the guidance figures.
- The company plans to complete a $50 million accelerated share repurchase before the end of 2026. Management also cited business development, debt repayment and potential shareholder returns as capital-allocation priorities.
- Collegium launched Start Talking ADHD, an online resource hub with downloadable guides intended to help people with ADHD and their families prepare for conversations with health-care providers, schools and support networks.
Plain-English implications
The reported figures show Collegium’s ADHD medicines are an increasingly significant part of its business, while the pain portfolio remains a major source of revenue. The planned share repurchase would return capital to shareholders; management also says it intends to balance that with business development and debt reduction.